Caplin Point Laboratories Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 12 Aug 2026

Company page: Caplin Point Laboratories share price, financials & guidance record

Caplin Point Laboratories delivered a strong Q1 FY27, marked by robust revenue growth across all segments, particularly in the US, and improved EBITDA margins. The company is aggressively investing in capacity expansion, digitalization, and strategic market entries, all funded through internal accruals. While cash flow from operations was temporarily impacted by inventory build-up, management expects improvement in subsequent quarters, maintaining a positive outlook for future growth and profitability.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 19.6%, net profit up 18.5% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	483	493	502	510	534 +11%	543 +10%	600 +20%	610 +20%
Expenses	318	331	334	332	345	353	396	397
EBITDA	165	162	168	178	189 +15%	190 +17%	204 +21%	213 +20%
Margin	34%	33%	33%	35%	35%	35%	34%	35%
Other income	21	31	26	23	30	34	28	34
Interest	0	0	0	0	0	0	0	0
Depreciation	17	16	17	16	18	19	19	22
Profit before tax	168	177	177	184	201 +20%	204 +15%	213 +20%	225 +22%
Tax rate	22%	21%	18%	18%	20%	19%	19%	20%
Net profit	131	140	145	151	160 +22%	166 +19%	173 +19%	179 +19%
EPS	17.21	18.28	18.76	20.10	20.32	21.56	22.38	23.27

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls